• Joseph V Pergolizzi, Gianpietro Zampogna, Robert Taylor, and Robert B Raffa.
• Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• Expert Rev Neurother. 2015 Mar 1; 15 (3): 231-8.

AbstractHistorically, chronic pain generally went under-treated for a variety of objective and subjective reasons, including difficulty to objectively diagnose and manage over a long period of time, potential serious adverse effects of commonly available medications, and patient, healthcare and societal concerns over opioid medications. More recently, in an effort to redress the under-treatment of pain, the number of prescriptions of opioid analgesics has risen dramatically. However, paralleling the increased legitimate use has been a concomitant increase in opioid abuse, misuse and diversion. Pharmaceutical companies have responded by developing a variety of opioid formulations designed to deter abuse by making the products more difficult to tamper with. One such product is Remoxy(®), an extended-release formulation of the strong opioid oxycodone. We review the efficacy, safety and tolerability of this formulation based on the available published literature.

20 keywords...

hide…